Adherium Ltd. (AU:ADR) has released an update.
Adherium Ltd. is poised for significant growth with plans to onboard over 600 patients by next quarter and a robust sales pipeline involving more than 50 healthcare organizations. The company is expanding into the Pharmacy Benefit Management sector, aiming to launch a program in early 2025 that could reach up to 250,000 patients. These strategic efforts, alongside the search for a new CEO, position Adherium for enhanced revenue generation and market expansion.
For further insights into AU:ADR stock, check out TipRanks’ Stock Analysis page.